MCL Featured Stories
This "Pathways" program provides Anatomic and Clinical Pathology cases that include a history, potential answers, rationale, and relevant references. Cases for July include the following sub-specialties: Breast Pathology, Cytopathology & Pulmonary Pathology, Dermatopathology, Clinical Microbiology, and Molecular Pathology.
Tying together the expertise and curiosity of Mayo Clinic autoimmune neurology researchers with eager patients who have rare disease and are looking for answers, the innovative collaboration benefits both patients affected by MOGAD and scientists on the front lines of discovery.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS panels.
Joe Mondloch and his wife Sue have existed in a grey area of uncertainty due to the unpredictable autoimmune neurological illness Joe has lived with for the last seven years. Rare, incurable, and debilitating, the newly classified disorder can be hard to manage. But thanks to information and direction provided by a rare disease advocacy group, the Mondlochs sought care at Mayo Clinic and received much more than answers.
In this “Hot Topic,” Paul Jannetto, Ph.D., highlights Mayo Clinic’s targeted benzodiazepine assay and discusses the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Clarissa Jordan, M.D., chief resident in anatomic and clinical pathology for the Department of Laboratory Medicine and Pathology at Mayo Clinic, to discuss online pathology resources.
This page includes updates posted to Mayo Clinic Labs during the month of June.
PACE / State of FL
This month’s “Virtual Lecture,” discusses how artificial intelligence can be utilized to classify kidney stones while demonstrating improvement in quality and patient safety.
Due to the upcoming Independence Day holiday on Tuesday, July 4, Mayo Clinic Laboratories' sample pickup and delivery schedules will be altered. To ensure sample viability and minimize test turnaround time delays, we have implemented several adjustments and guidelines.
The spectrum of autoimmune movement disorders, diagnosis and treatment.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Isabella Holmes, D.O., a first-year pathology resident at Michigan State, to discuss her residency training experience.
VEXAS syndrome is a severe autoinflammatory disease that results in a spectrum of rheumatologic and hematologic conditions. The underlying cause of newly identified VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome — somatic mutations in the UBA1 gene of blood cells — was discovered at the National Institutes of Health (NIH) in 2020. Within six months, Mayo Clinic Laboratories was able to add a UBA1 test to the MayoComplete panel, as the team simultaneously worked on a single gene assay to allow doctors to test specifically for UBA1 mutations to screen patients for VEXAS syndrome. The team opted for a droplet digital PCR test — a novel and highly accurate approach to testing for UBA1 gene mutations.